Literature DB >> 34073249

Old and New Challenges in Uveitis Associated with Behçet's Disease.

Julie Gueudry1, Mathilde Leclercq2, David Saadoun3,4,5, Bahram Bodaghi6.   

Abstract

Behçet's disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage. The aim of this review is to provide current data on how innovations in clinical evaluation, investigations and treatments were able to improve the prognosis of uveitis associated with BD.

Entities:  

Keywords:  Behçet’s disease; anti-TNFα agent; biologics; retinal vasculitis; tocilizumab; uveitis

Year:  2021        PMID: 34073249     DOI: 10.3390/jcm10112318

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  142 in total

1.  Adalimumab: a new modality for Behçet's disease?

Authors:  J A M van Laar; T Missotten; P L A van Daele; A Jamnitski; G S Baarsma; P M van Hagen
Journal:  Ann Rheum Dis       Date:  2006-11-23       Impact factor: 19.103

Review 2.  Behçet's disease: ocular effects and treatment.

Authors:  Christoph M E Deuter; Ina Kötter; Graham R Wallace; Philip I Murray; Nicole Stübiger; Manfred Zierhut
Journal:  Prog Retin Eye Res       Date:  2007-11-26       Impact factor: 21.198

3.  2018 update of the EULAR recommendations for the management of Behçet's syndrome.

Authors:  Gulen Hatemi; Robin Christensen; Dongsik Bang; Bahram Bodaghi; Aykut Ferhat Celik; Farida Fortune; Julien Gaudric; Ahmet Gul; Ina Kötter; Pietro Leccese; Alfred Mahr; Robert Moots; Yesim Ozguler; Jutta Richter; David Saadoun; Carlo Salvarani; Francesco Scuderi; Petros P Sfikakis; Aksel Siva; Miles Stanford; Ilknur Tugal-Tutkun; Richard West; Sebahattin Yurdakul; Ignazio Olivieri; Hasan Yazici
Journal:  Ann Rheum Dis       Date:  2018-04-06       Impact factor: 19.103

Review 4.  [Ocular manifestations in Behçet's disease].

Authors:  A-C Desbois; C Terrada; P Cacoub; B Bodaghi; D Saadoun
Journal:  Rev Med Interne       Date:  2018-04-04       Impact factor: 0.728

5.  Expert opinion on the use of biological therapy in non-infectious uveitis.

Authors:  Sara Touhami; Eléonore Diwo; Pascal Sève; Salim Trad; Philip Bielefeld; Damien Sène; Sebastien Abad; Antoine Brézin; Pierre Quartier; Isabelle Koné Paut; Michel Weber; Christophe Chiquet; Marie-Hélène Errera; Jérémie Sellam; Patrice Cacoub; Gilles Kaplanski; Laurent Kodjikian; Bahram Bodaghi; David Saadoun
Journal:  Expert Opin Biol Ther       Date:  2019-04-16       Impact factor: 4.388

6.  Golimumab treatment for complicated uveitis.

Authors:  Elisabetta Miserocchi; Giulio Modorati; Irene Pontikaki; Pierluigi Meroni; Valeria Gerloni
Journal:  Clin Exp Rheumatol       Date:  2013-01-18       Impact factor: 4.473

7.  Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.

Authors:  Cristina Mugheddu; Laura Atzori; Maria Del Piano; Astrid Lappi; Monica Pau; Severino Murgia; Ignazio Zucca; Franco Rongioletti
Journal:  Dermatol Ther       Date:  2017-08-18       Impact factor: 2.851

8.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

9.  Long-term treatment with golimumab for severe uveitis.

Authors:  Elisabetta Miserocchi; Giulio Modorati; Irene Pontikaki; Pier Luigi Meroni; Valeria Gerloni
Journal:  Ocul Immunol Inflamm       Date:  2013-10-21       Impact factor: 3.070

10.  Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy.

Authors:  Hilal Eser Ozturk; Merih Oray; Ilknur Tugal-Tutkun
Journal:  Ocul Immunol Inflamm       Date:  2017-10-11       Impact factor: 3.070

View more
  1 in total

1.  Management of Non-Infectious Uveitis, a Selection of Topical Items Updating.

Authors:  Pascal Sève; Thomas El Jammal; Mathieu Gerfaud-Valentin; Laurent Kodjikian; Yvan Jamilloux; Robin Jacquot
Journal:  J Clin Med       Date:  2022-09-22       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.